Edition:
United States

Affimed NV (AFMD.OQ)

AFMD.OQ on NASDAQ Stock Exchange Global Market

1.50USD
16 Aug 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$1.50
Open
$1.50
Day's High
$1.55
Day's Low
$1.50
Volume
7,003
Avg. Vol
45,829
52-wk High
$2.85
52-wk Low
$1.17

Latest Key Developments (Source: Significant Developments)

Affimed Reports Q2 Loss Per Share EUR 0.13
Wednesday, 8 Aug 2018 07:30am EDT 

Aug 8 (Reuters) - Affimed NV ::AFFIMED REPORTS FINANCIAL RESULTS FOR SECOND QUARTER 2018 AND OPERATIONAL PROGRESS.Q2 LOSS PER SHARE EUR 0.13.Q2 REVENUE EUR 200,000 VERSUS EUR 500,000.Q2 REVENUE VIEW EUR 407,000 -- THOMSON REUTERS I/B/E/S.Q2 EARNINGS PER SHARE VIEW EUR -0.15 -- THOMSON REUTERS I/B/E/S.CASH AND CASH EQUIVALENTS TOTALED EUR 47.4 MILLION AS OF JUNE 30, 2018 COMPARED TO EUR 39.8 MILLION AS OF DECEMBER 31, 2017.  Full Article

Affimed Reports Q4 Loss Per Share EUR 0.14
Tuesday, 20 Mar 2018 07:30am EDT 

March 20 (Reuters) - Affimed Nv ::AFFIMED REPORTS FINANCIAL RESULTS FOR FOURTH QUARTER AND YEAR END 2017.Q4 LOSS PER SHARE EUR 0.14.Q4 EARNINGS PER SHARE VIEW EUR -0.17 -- THOMSON REUTERS I/B/E/S.Q4 REVENUE EUR 600,000 VERSUS EUR 1.4 MILLION.Q4 REVENUE VIEW EUR 1.8 MILLION -- THOMSON REUTERS I/B/E/S.‍OPERATIONS, INCLUDING CLINICAL DEVELOPMENT AND EARLY DEVELOPMENT ACTIVITIES, ARE EXPECTED TO BE FUNDED AT LEAST UNTIL Q4 OF 2019​.  Full Article

Affimed prices 11.5 mln common shares at $2 per share
Tuesday, 13 Feb 2018 03:00am EST 

Feb 13 (Reuters) - Affimed Nv ::AFFIMED ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 11.5 MILLION COMMON SHARES PRICED AT $2.00PER SHARE.  Full Article

Affimed Announces Proposed Public Offering Of Common Stock
Monday, 12 Feb 2018 04:04pm EST 

Feb 12 (Reuters) - Affimed Nv ::AFFIMED ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.  Full Article

Affimed Reports New Data For AFM13 From Two Separate Clinical Trials
Thursday, 1 Feb 2018 08:30am EST 

Feb 1 (Reuters) - Affimed Nv ::AFFIMED REPORTS NEW DATA FOR AFM13 FROM TWO SEPARATE CLINICAL TRIALS IN HODGKIN AND CD30-POSITIVE LYMPHOMAS.AFFIMED NV - ‍DATA DEMONSTRATE THAT AFM13 WAS WELL-TOLERATED​.AFFIMED NV - ‍DATA DEMONSTRATE AFM13 IN COMBINATION WITH KEYTRUDA® (PEMBROLIZUMAB) DOUBLED COMPLETE RESPONSE RATE IN HODGKIN LYMPHOMA PATIENTS​.AFFIMED NV - ‍EARLY DATA SUGGEST NEW OPPORTUNITY FOR AFM13 IN CD30-POSITIVE LYMPHOMA​.AFFIMED NV - ‍AFM13 IS CLINICALLY ACTIVE AND WELL-TOLERATED AS MONO- AND COMBINATION THERAPY​.AFFIMED NV - ‍ AFM13 IN COMBINATION WITH KEYTRUDA WAS WELL-TOLERATED WITH MOST OF ADVERSE EVENTS OBSERVED MILD TO MODERATE IN NATURE.  Full Article

Affimed reports Q3 loss per share EUR 0.18
Tuesday, 7 Nov 2017 07:30am EST 

Nov 7 (Reuters) - Affimed Nv :Affimed reports financial results for third quarter 2017.Q3 loss per share EUR 0.18.Q3 earnings per share view EUR -0.17 -- Thomson Reuters I/B/E/S.Q3 revenue eur 500,000 versus EUR 900,000.Q3 revenue view EUR 933,000 -- Thomson Reuters I/B/E/S.  Full Article

Affimed announces Q3 financial results and corporate update conference call
Monday, 30 Oct 2017 06:01am EDT 

Oct 30 (Reuters) - Affimed Nv :Affimed announces third quarter 2017 financial results and corporate update conference call.  Full Article

Affimed posts Q2 loss of EUR 0.18 per share
Tuesday, 1 Aug 2017 07:30am EDT 

Aug 1 (Reuters) - Affimed Nv :Affimed reports financial results for second quarter 2017.Q2 loss per share EUR 0.18.Q2 earnings per share view EUR -0.20 -- Thomson Reuters I/B/E/S.Q2 revenue EUR 500,000 versus EUR 2.1 million.Q2 revenue view EUR 1.2 million -- Thomson Reuters I/B/E/S.Cash and cash equivalents and financial assets totaled EUR 48.9 million as of June 30, 2017.  Full Article

Affimed reports Q1 loss per share EUR 0.19
Wednesday, 17 May 2017 07:30am EDT 

May 17 (Reuters) - Affimed NV :Affimed reports financial results for first quarter 2017.Q1 loss per share eur 0.19.Q1 revenue EUR 400,000 versus EUR 1.9 million.Q1 revenue view EUR 1.5 million -- Thomson Reuters I/B/E/S.Q1 earnings per share view eur -0.21 -- Thomson Reuters I/B/E/S.Affimed NV - cash and cash equivalents and financial assets totaled eur 53.7 million as of march 31, 2017 compared to eur 44.9 million as of december 31, 2016.  Full Article

Affimed reports Q4 loss per share EUR 0.16
Thursday, 30 Mar 2017 07:31am EDT 

Affimed NV : Affimed reports financial results for fourth quarter and year end 2016 . Q4 loss per share eur 0.16 . Q4 earnings per share view EUR -0.29 -- Thomson Reuters I/B/E/S . Q4 revenue EUR 1.4 million versus EUR 1.7 million . Q4 revenue view EUR 1.1 million -- Thomson Reuters I/B/E/S .Affimed NV - including proceeds from offering in January and February 2017, company's operations are expected to be funded at least until end of 2018.  Full Article